High deferral rate for maternal–neonatal donor pairs for an allogeneic umbilical cord blood bank

Corresponding Author

Leigh C. Jefferies MD

Assistant Director

Blood Bank, Transfusion Medicine Section, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania

Associate Professor, Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, 6078 Founders Pavilion, 3400 Spruce Street, Philadelphia, PA 19104.Search for more papers by this author

Mary Albertus RN,

Mary Albertus RN

Nurse Coordinator

Umbilical Cord Blood Program, Department of Pathology and Laboratory Medicine, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania

Search for more papers by this author

Mark A. Morgan MD,

Mark A. Morgan MD

Director

Obstetrics and Maternal-Fetal Medicine, University of Pennsylvania Medical Center; and Associate Professor, Department of Obstetrics and Gynecology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania

Search for more papers by this author

David Moolten MD,

David Moolten MD

Medical Director

Blood Services, American Red Cross, Penn-Jersey Region, Philadelphia, PA; and Adjunct Assistant Professor, Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania

Search for more papers by this author

Leigh C. Jefferies MD,

Corresponding Author

Leigh C. Jefferies MD

Assistant Director

Blood Bank, Transfusion Medicine Section, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania

Mary Albertus RN,

Mary Albertus RN

Nurse Coordinator

Umbilical Cord Blood Program, Department of Pathology and Laboratory Medicine, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania

Search for more papers by this author

Mark A. Morgan MD,

Mark A. Morgan MD

Director

Search for more papers by this author

David Moolten MD,

David Moolten MD

Medical Director

Search for more papers by this author

First published: 19 December 2002

https://doi.org/10.1046/j.1537-2995.1999.39499235676.x

Citations: 15

Supported in part by grant number PO1-HL-54516-02 from the Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.

Share a link

Email
Wechat
Bluesky

Abstract

BACKGROUND: To fully evaluate the safety and efficacy of umbilical cord blood (UCB) as a source of hematopoietic progenitor cells, UCB banks are being established worldwide to provide a readily accessible resource of stem and progenitor cells for allogeneic transplantation. Guidelines for UCB donor criteria have been proposed to minimize the possibility of disease transmission to UCB recipients.

STUDY DESIGN AND METHODS: In preparation for the establishment of an allogeneic UCB bank, 285 maternal–neonatal donor pairs were evaluated in our tertiary-care hospital, which was chosen because of the high percentage of African Americans among the maternal population. Maternal, neonatal, and family histories were obtained by confidential interview and medical record review to determine the number of eligible donor pairs on the basis of a conservative interpretation of proposed donor criteria.

RESULTS: Only 44 percent of donor pairs were considered eligible. The most common deferral factors were maternal, and they included fever at delivery, history of chronic disease, and history of sexually transmitted disease. In most cases, more than one deferral factor was identified.

CONCLUSIONS: High-risk maternal populations, which may provide access to ethnic minorities targeted for some UCB banks, may contain low percentages of eligible donors. Further refinement of donor criteria will be important in the evolution of UCB banking and transplantation.

REFERENCES

1 Kurtzberg J, Laughlin M, Graham ML. Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. N Engl J Med 1996; 335: 157–66.
10.1056/NEJM199607183350303
CAS PubMed Web of Science® Google Scholar
2 Wagner JE, Kernan NA, Steinbuch M, et al. Allogeneic sibling umbilical-cord-blood transplantation in children with malignant and non-malignant disease. Lancet 1995; 346: 214–9.
10.1016/S0140-6736(95)91268-1
CAS PubMed Web of Science® Google Scholar
3 Wagner JE, Rosenthal J, Sweetman R, et al. Successful transplantation of HLA-matched and HLA-mismatched umbilical cord blood from unrelated donors: analysis of engraftment and acute graft-versus-host disease. Blood 1996; 88: 795–802.
10.1182/blood.V88.3.795.795
CAS PubMed Web of Science® Google Scholar
4 Gluckman E, Rocha V, Boyer-Chammard A, et al. Outcome of cord-blood transplantation from related and unrelated donors. N Engl J Med 1997; 337: 373–81.
10.1056/NEJM199708073370602
CAS PubMed Web of Science® Google Scholar
5 Broxmeyer HE. Questions to be answered regarding umbilical cord blood hematopoietic stem and progenitor cells and their use in transplantation. Transfusion 1995; 35: 694–702.
10.1046/j.1537-2995.1995.35895357903.x
CAS PubMed Web of Science® Google Scholar
6 McCullough J, Clay ME, Fautsch S, et al. Proposed policies and procedures for the establishment of a cord blood bank. Blood Cells 1994; 20: 609–26.
CAS PubMed Web of Science® Google Scholar
7 Beatty PG, Kollman C, Howe CW. Unrelated-donor marow transplants: the experience of the National Marrow Donor Program. In: JM Cecka, PI Terasaki eds., Clinical Transplants. Los Angeles: UCLA Tissue Typing Laboratory, 1995: 271–7.
Google Scholar
8 Blood donor interview, processing, and management. Blood Services Directive 51.110. American Red Cross Blood Services. July 27, 1992. Amendment VII Effective April 25, 1996. Washington: American Red Cross, 1992.
Google Scholar
9 Rubinstein P, Taylor PE, Scaradavou A, et al. Unrelated placental blood for bone marrow reconstitution: organization of the placental blood program. Blood Cells 1994; 20: 587–96; discussion 596–600.
PubMed Web of Science® Google Scholar
10 Matsuua N, Konishi J, Fujieda K, et al. TSH-receptor antibodies in mothers with Graves' disease and outcome in their offspring. Lancet 1988; 1: 14–7.
Google Scholar
11 Maddison PJ. The neonatal lupus syndrome. Clin Exp Rheumatol 1988; 6: 169–72.
CAS PubMed Web of Science® Google Scholar
12 Bassett JM, Madill D. Influence of prolonged glucose infusions on plasma insulin and growth hormone concentrations of fetal lambs. J Endocrinol 1974; 62: 299–309.
10.1677/joe.0.0620299
CAS PubMed Google Scholar
13 Freinkel N. Banting Lecture 1980. Of pregnancy and progeny. Diabetes 1980; 29: 1023–35.
10.2337/diab.29.12.1023
CAS PubMed Web of Science® Google Scholar
14 Sibai BM, Anderson GO. Pregnancy outcome of intensive therapy in severe hypertension in first trimester. Obstet Gynecol 1986; 67: 517–22.
CAS PubMed Web of Science® Google Scholar
15 Naden RP, Redman CW. Antihypertensive drugs in pregnancy. Clin Perinatol. 1985; 12: 521–38.
10.1016/S0095-5108(18)30853-4
CAS PubMed Web of Science® Google Scholar
16 Hiett AK, Britton KA, Hauge NL, et al. Comparison of hematopoietic progenitor cells in human umbilical cord blood collected from neonatal infants who are small and appropriate for gestational age. Transfusion 1995; 35: 587–91.
10.1046/j.1537-2995.1995.35795357882.x
CAS PubMed Web of Science® Google Scholar
17 Infection and disorders of the puerperium. In: FG Cunningham, PC MacDonald, NF Gant, et al. eds. Williams obstetrics. Stamford, CT: Appleton & Lange, 1997: 547–61.
Google Scholar
18 Vintzileos AM. Amnionitis. Contemp Obstet Gynecol 1994; 39: 75–8.
Google Scholar
19 Gibbs RS, Sweet RL. Clinical disorders. In: RK Creasy, R Resnik, eds. Maternal-fetal medicine: principles and practice. Philadelphia: Saunders, 1994: 639–703.
Google Scholar
20 Volpe JJ. Effect of cocaine use on the fetus. N Engl J Med 1992; 327: 399–407.
10.1056/NEJM199208063270607
CAS PubMed Web of Science® Google Scholar
21 Donohoe RM, Falek A, Madden JJ, et al. Effect of cocaine and other drugs of abuse on immune function. In: H Friedman, S Specter, TW Klein eds., Drugs of abuse, immunity, and immunodeficiency. New York: Plenum Press, 1991: 143–50.
Google Scholar
22 Clarification of FDA recommendations for donor deferral and product distribution based on the results of syphilis testing. Memorandum issued by CBER. Rockville, MD: Food and Drug Administration, December 12, 1991.
Google Scholar
23 Recommendations for the prevention of human immunodeficiency virus transmission by blood and blood products. Revised and issued by CBER. Rockville, MD: Food and Drug Administration, April 23, 1992.
Google Scholar

Citing Literature

Volume39, Issue4

April 1999

Pages 415-419

High deferral rate for maternal–neonatal donor pairs for an allogeneic umbilical cord blood bank

Abstract

REFERENCES

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

High deferral rate for maternal–neonatal donor pairs for an allogeneic umbilical cord blood bank

Abstract

REFERENCES

Citing Literature

References

Related

Information